首页> 外文OA文献 >A novel polyethylene glycol ( PEG )‐drug conjugate of Venetoclax, a Bcl‐2 inhibitor, for treatment of acute myeloid leukemia ( AML )

【2h】

A novel polyethylene glycol ( PEG )‐drug conjugate of Venetoclax, a Bcl‐2 inhibitor, for treatment of acute myeloid leukemia ( AML )

机译：一种新型聚乙二醇（PEG） - 威尼替肽，BCL-2抑制剂的缀合物，用于治疗急性髓性白血病（AML）

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Hidenori Ando; Yuta Murakami; Kiyoshi Eshima; Tatsuhiro Ishida;
展开▼
作者单位

展开▼
年度 2021
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Clinical experience with the BCL BCL 2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies [J] . DiNardo Courtney D., Rausch Caitlin R., Benton Christopher, American Journal of Hematology . 2018,第3期

机译：与BCL BCL 2抑制剂venetoclax的临床经验在联合治疗中复发和难治性急性髓性白血病和相关霉菌性恶性肿瘤
2. Voruciclib, an Oral, Selective CDK9 Inhibitor, Enhances Cell Death Induced By the Bcl-2 Selective Inhibitor Venetoclax in Acute Myeloid Leukemia [J] . Luedtke Daniel A., Su Yongwei, Edwards Holly, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：Voruciclib，口服选择性CDK9抑制剂，增强了Bcl-2选择性抑制剂venetoclax在急性髓性白血病中诱导的细胞死亡
3. Cytogenetics and mutations could predict outcome in relapsed and refractory acute myeloid leukemia patients receiving BCL-2 inhibitor venetoclax [J] . Wang Yu-Wen, Tsai Cheng-Hong, Lin Chien-Chin, Annals of hematology . 2020,第3期

机译：细胞遗传学和突变可以预测接受Bcl-2抑制剂venetoclax的复发和难治性急性髓性白血病患者的结果
4. Chemical proteomic identification of targets for antibody-drug conjugate based therapy in acute myeloid leukemia [C] . V. Strassberger, T. Fugmann, D. Neri American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics . 2012

机译：基于抗体药物缀合物的靶向急性髓性白血病疗法的化学蛋白质组学鉴定
5. Comparison of FLT3 Inhibitors with the Standard Treatment for FLT3-ITD Mutated Acute Myeloid Leukemia [D] . Argetsinger, Stephanie. 2018

机译：FLT3抑制剂对FLT3-ITD突变急性髓性白血病标准治疗的比较
6. 225Ac‐labeled CD33‐targeting antibody reverses resistance to Bcl‐2 inhibitor venetoclax in acute myeloid leukemia models [O] . Ravendra Garg, Kevin J. H. Allen, Wojciech Dawicki, 2021

机译：标记的CD33靶向抗体抗体在急性髓性白血病模型中反转对BCL-2抑制剂venetoclax的抗性
7. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies [O] . Courtney D. DiNardo, Caitlin R. Rausch, Christopher Benton, 2017

机译：与BCL2抑制剂venetoclax的临床经验在联合治疗中复发和难治性急性髓性白血病和相关霉菌性恶性肿瘤

A novel polyethylene glycol ( PEG )‐drug conjugate of Venetoclax, a Bcl‐2 inhibitor, for treatment of acute myeloid leukemia ( AML )

著录项

引文网络

相似文献

相关主题

期刊订阅